The pharmaceutical industry is experiencing a seismic shift as AI transcends traditional human limitations. The scientific evidence base is exploding beyond human capacity as thousands of studies that could transform patient care are published daily. But we're falling further behind in our ability to synthesize this knowledge when decisions need to be made. AI agents are moving from pilots to production, fundamentally changing how we engage with scientific literature. Sanofi, Biolevate and NVIDIA share their journey of scaling AI agents to an enterprise level—now managing 100,000+ agents and millions of workloads—turning massive evidence bases into timely and actionable decisions. But can this productivity boost genuinely reshape how we work? And what does responsible scaling in pharma look like?
